NASDAQ:ATNF - Nasdaq - US68236V3024 - Common Stock - Currency: USD
180 LIFE SCIENCES CORP
NASDAQ:ATNF (2/5/2025, 2:46:08 PM)
1.39
+0.02 (+1.46%)
The current stock price of ATNF is 1.39 USD. In the past month the price decreased by -20.35%. In the past year, price decreased by -64.2%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.97 | 339.20B | ||
AMGN | AMGEN INC | 15.47 | 164.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 962.18 | 126.37B | ||
GILD | GILEAD SCIENCES INC | 22.6 | 124.75B | ||
REGN | REGENERON PHARMACEUTICALS | 15.76 | 79.05B | ||
ARGX | ARGENX SE - ADR | N/A | 40.07B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
BNTX | BIONTECH SE-ADR | N/A | 29.56B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.35B | ||
NTRA | NATERA INC | N/A | 23.36B | ||
BIIB | BIOGEN INC | 8.95 | 21.31B | ||
UTHR | UNITED THERAPEUTICS CORP | 15.63 | 15.89B |
180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company is headquartered in Palo Alto, California and currently employs 4 full-time employees. The company went IPO on 2017-06-07. The firm is focused on iGaming sector, through its iGaming Technology Platform. The firm also continues to evaluate monetization strategies for its biotechnology assets.
180 LIFE SCIENCES CORP
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto CALIFORNIA 10019 US
CEO: James N. Woody
Employees: 4
Company Website: https://180lifesciences.com/
Phone: 16505070669
The current stock price of ATNF is 1.39 USD.
The exchange symbol of 180 LIFE SCIENCES CORP is ATNF and it is listed on the Nasdaq exchange.
ATNF stock is listed on the Nasdaq exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ATNF, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ATNF.
ATNF does not pay a dividend.
ATNF does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.49).
The outstanding short interest for ATNF is 7.5% of its float.
ChartMill assigns a fundamental rating of 2 / 10 to ATNF. ATNF may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ATNF reported a non-GAAP Earnings per Share(EPS) of -4.49. The EPS decreased by 98.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -29.82% | ||
ROE | -83.61% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ATNF. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 50% and a revenue growth 481.87% for ATNF